Selective enzymatic debridement ointment that gently removes necrotic tissue while preserving healthy granulation tissue. Santyl collagenase ointment provides continuous wound bed preparation between clinical visits for diabetic foot ulcers, pressure sores, venous leg ulcers, and surgical wounds - proven effective for over 60 years. FDA-approved enzymatic debridement. Medicare Part B covered mobile wound care in Beverly Hills, Orange County, Los Angeles County, San Fernando Valley, Riverside County, San Bernardino County, Ventura County, Santa Barbara County, Kern County, and San Luis Obispo County.
An FDA-approved enzymatic debriding ointment that selectively removes necrotic tissue while preserving healthy wound bed tissue
Santyl contains collagenase enzyme derived from Clostridium histolyticum bacteria. This FDA-approved ointment selectively breaks down collagen in necrotic tissue, enabling natural removal of dead tissue while leaving healthy granulation tissue completely intact.
Unlike sharp or surgical debridement, Santyl provides gentle, continuous enzymatic action that's ideal for fragile wounds, elderly patients, and wounds requiring ongoing maintenance between clinical visits. Applied once daily under appropriate moisture-retentive dressings.
This selectivity makes Santyl® ideal for patients who cannot tolerate sharp debridement, those on anticoagulants, or wounds with fragile granulation tissue that needs protection during the debridement process.
60+ Years
Proven clinical efficacy and safety profile
Digests only denatured collagen in necrotic tissue—healthy granulation remains intact
Applied once daily directly to wound bed—works continuously between visits
Covered under Medicare Part B and most major insurance plans
How Santyl® enzymatically removes necrotic tissue
Proteolytic enzyme cleaves peptide bonds in denatured collagen strands within necrotic tissue
Slough and eschar are liquefied and naturally removed by the body's immune response
Healthy granulation tissue remains intact, promoting faster epithelialization and closure
Enzymatic debridement is particularly effective for chronic wounds with necrotic burden
Removes yellow slough and fibrin without sharp instruments—ideal for neuropathic wounds
Gentle, continuous debridement for Stage III/IV ulcers in bedridden or immobile patients
Maintains clean wound bed between compression therapy visits and prevents biofilm
Maintains wound bed hygiene after initial sharp debridement—reduces need for repeat procedures
Multiple randomized controlled trials demonstrate Santyl®'s superiority in achieving complete wound closure compared to placebo and other enzymatic agents. FDA-approved since 1960 with an extensive safety profile.
Our wound care specialists will assess your wound and determine if enzymatic debridement is the right treatment option for you.